LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Levels of NfL Increase Accuracy of Stroke Risk Prediction

By LabMedica International staff writers
Posted on 08 Jul 2019
Print article
Image: A micrograph of the superficial cerebral cortex showing neuron loss and reactive astrocytes in a person that has had a stroke (Photo courtesy of Wikimedia Commons).
Image: A micrograph of the superficial cerebral cortex showing neuron loss and reactive astrocytes in a person that has had a stroke (Photo courtesy of Wikimedia Commons).
Serum levels of neurofilament light polypeptide have been found to predict the likelihood of suffering a stroke and to add considerably to the discriminatory power of the Framingham Stroke Risk Score in a group of middle-aged and older adults with diabetes mellitus.

Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and blood serum and plasma that reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.

As effective stroke prevention depends on accurate stroke risk prediction, investigators at the University of Michigan (Ann Arbor, USA) examined the discriminative ability of NfL levels for distinguishing between adults with diabetes mellitus who developed incident stroke and those who remained stroke free during a seven-year follow-up period.

The investigators performed a case-control study of participants selected from the previously completed ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). The 113 cases were all ACCORD subjects who were stroke free at enrollment and developed incident stroke during follow-up. A group of 250 control subjects comprised randomly selected ACCORD subjects who had no stroke events either before or after randomization. NfL levels were measured in baseline samples using Quanterix (Billerica, MA, USA) Single Molecule Array technology.

Results revealed that subjects who developed a stroke had blood levels of NfL that were about 43% higher than those who did not develop a stroke. In contrast, those with the highest NfL levels were 10 times more likely to develop a stroke during the seven-year follow-up period, than those with low levels of NfL.

In addition, the results showed that older age, nonwhite race, higher systolic blood pressure, glomerular filtration rate less than 60, and higher hemoglobin A1C were independent predictors of serum NfL in this cohort, but that diastolic blood pressure, durations of hypertension or diabetes mellitus, and lipid levels were not.

First author Dr. Frederick Korley, assistant professor of emergency medicine at the University of Michigan, said, "The Framingham Stroke Risk Score looks at stroke risk factors in a patient and predicts 10-year probability of a stroke occurring. The score currently includes factors such as diabetes, current smoking status, and blood pressure. When we added NfL levels as a risk factor, the score appeared to become even more accurate in predicting stroke."

The NfL study was published in the July 1, 2019, issue of the journal Stroke.

Related Links:
University of Michigan
Quanterix

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more